Researchers at Eindhoven University of Technology in the Netherlands are developing AquaWomb, an artificial womb for extremely premature babies (under 28 weeks). It uses synthetic amniotic fluid and an artificial placenta to support development outside the body. Clinical trials are still about 5–6 years away, and the project raises major ethical and social questions.
Babies born at this stage may weigh as little as 506 grams, and their underdeveloped lungs and brains prevent them from breathing independently. While current hospital ventilators can support survival, they may also cause harm to fragile, developing airways. The AquaWomb aims to address this problem by recreating a womb-like environment where organs can continue maturing naturally.
Artificial wombs as backup, not replacement
Researchers emphasize that the technology is not intended to replace natural pregnancy. They argue that the womb remains the best environment for fetal development, so clinicians would only use the device as a last resort in cases of extreme prematurity. Still, it raises complex questions about medical use, access, cost, and the limits of reproductive technology.
The most severe cases involve babies born before 28 weeks, considered extremely premature. In these cases, the first days of life are critical, and survivors may have long-term complications such as developmental, vision, hearing, and respiratory problems. The artificial womb aims to extend development time that would normally occur in the uterus.
The AquaWomb addresses a key challenge: at birth, a baby’s lungs must switch to air breathing, a one-way change. Ventilators can sustain life but may damage immature lungs. An artificial womb instead keeps the lungs in fluid, like in the uterus, allowing safer, more gradual development. The concept is straightforward in theory but highly complex in practice.
Clinicians place the premature infant in artificial amniotic fluid, keeping its lungs in the same fluid-filled state as in the womb. They attach the umbilical cord to an artificial placenta—similar to a medical oxygenator—that continuously supplies oxygen and nutrients. The baby’s own heart circulates blood through this external system, just as it would during gestation.
To prevent lung exposure to air during transition, Eindhoven researchers developed a specialized transfer method that keeps the infant fully submerged throughout delivery into the system. A separate mechanism constantly filters the fluid, removing waste and maintaining stable conditions. Once the lungs are sufficiently developed, typically around 28 weeks, clinicians transition the infant into a standard incubator. In this framework, the artificial womb serves as a temporary bridge between extreme prematurity and survival outside the womb.
Early animal research demonstrates feasibility of artificial wombs
The Eindhoven project builds on earlier research. In 2017, U.S. scientists kept a premature lamb alive and developing for weeks in an artificial womb, showing that immature lungs can continue maturing outside the body. While not directly applicable to humans, it confirmed the biological feasibility of the approach.
In 2021, Israeli researchers grew mouse embryos in rotating incubators long enough to observe early organ and limb development outside the uterus, advancing earlier lamb embryo studies and broader developmental research. Together, they illustrate steady progress toward expanding what is technically possible in reproductive and developmental biology.
The AquaWomb is still in its early development phase. Researchers in Eindhoven say clinical trials will likely take at least five to six years before the system can be used in humans. That timeline is substantial, and during it both technological capabilities and regulatory frameworks may evolve significantly. Before use in infants, the device requires extensive safety validation, and approval processes are slow and highly stringent.
The researchers also acknowledge a major issue of accessibility. The system would likely be very expensive, yet most extreme preterm births occur in South Asia and sub-Saharan Africa, where healthcare resources are limited. Although these regions could benefit most, lack of infrastructure may prevent access, meaning the technology would mainly serve well-equipped neonatal intensive care units rather than areas with the greatest need.
From emergency care to the broader idea of ectogenesis
An artificial womb designed for extremely premature infants serves a narrow, emergency medical purpose. However, the same underlying principle—supporting fetal development outside the human body—also relates conceptually to ectogenesis, the idea of complete development from embryo to birth outside the uterus. Although AquaWomb does not aim to do this, further progress in the field could theoretically lead in that direction.
The boundary between development inside and outside the human body is already becoming less distinct. IVF and advanced neonatal intensive care have extended viability earlier in gestation. Artificial womb research continues this trajectory. As survivability advances earlier in fetal development, clinicians and researchers shift the question from whether full ectogenesis is possible to when it will be feasible and under what ethical and medical conditions they should allow it.
Giulia Cavaliere, a scholar of reproductive technologies, challenges the idea that artificial wombs would automatically be liberating for women. While the idea is appealing—suggesting greater freedom and reduced physical and professional burdens—she urges caution. Cavaliere argues existing reforms can achieve many goals and warns that overhyping future solutions distracts from current problems.
Ectogenesis and the risk of deepening inequality and control over reproduction
She also argues that even if full ectogenesis is achieved, it may not reduce—and could even worsen—gender inequality. Unequal access through income, geography, or healthcare systems could deepen existing divides. Since pregnancy is already politically regulated, artificial wombs would not automatically increase freedom and would raise new concerns about control and reproductive agency.
The Eindhoven AquaWomb researchers present it as an emergency medical device but recognize its wider societal implications. They call for broad public debate on its development, governance, access, and who should control it. Each stakeholder would bring different priorities, and commercialization could introduce dynamics that are difficult for medicine alone to regulate.
This debate is unfolding alongside intense global discussions about reproductive rights. Introducing technology that could sustain pregnancy outside the human body raises major ethical, legal, and economic questions. While artificial wombs may help save extremely premature infants, their broader societal role remains uncertain and calls for greater public engagement.
Read the original article on: clickpetroleoegas
Read more:Simple Color Indicator Makes Prosthetic Devices Easier to Master